Jefferies analyst Cui Cui maintained a Buy rating on Wuxi Biologics (Cayman) (WXIBF – Research Report) today and set a price target of ...

The German firm licensed a PRMT5 inhibitor that’s now in Phase 1 testing. Elsewhere, GSK is testing an intriguing hypothesis ...

We forecast WuXi's revenue growth to be slower than that of other well-established peers. The risk is high that the US Biosecure Act will become law, and we expect global pharmaceutical or ...

Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) service company offering end-to-end solutions for ...

To help you manage symptoms of AS, a doctor may recommend a therapy called biologics. AS primarily affects the spinal joints, but large joints, such as the hips and shoulders, can also be involved.

7 A family member caregiver of an RSV patient (name withheld on the caregiver's request) interviewed by GSK, shared, "As a caregiver, watching a loved one struggle with RSV is incredibly challenging.

Leader in Green CRDMO to drive innovation for a healthier future SHANGHAI, March 10, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development ...

The company was ranked top in its industry and received a Top 1% S&P Global Corporate Sustainability Assessment (CSA) Score, marking the third year WuXi Biologics has received this highest level ...

India's Syngene International on Monday said it has acquired its first biologics facility in the United States from Emergent Manufacturing Operations Baltimore, a unit of Emergent BioSolutions, for ...

Biocon's contract research arm Syngene International today said it has inked a drug discovery agreement with global drug firm GSK. The multi-year R&D agreement between the two companies will focus on ...

Welcome to Lab Dish, a new First Opinion column on regenerative medicine from Paul Knoepfler. With all the uncertainties surrounding the Food and Drug Administration under Trump 2.0, the recent ...